An­oth­er one bites the dust: Bris­tol My­ers Squibb pulls 'dan­gling' ac­cel­er­at­ed ap­proval for Op­di­vo in liv­er can­cer

Bris­tol My­ers Squibb has agreed to pull a sec­ond-line liv­er can­cer in­di­ca­tion for its block­buster Op­di­vo as a monother­a­py, be­com­ing the sec­ond PD-(L)1 in­di­ca­tion to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER